2024
Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee. Clinical Infectious Diseases 2024, ciae243. PMID: 38913762, DOI: 10.1093/cid/ciae243.Peer-Reviewed Original ResearchCenters for Disease Control and PreventionIncrease HIV testingHuman immunodeficiency virus testingHuman immunodeficiency virusPriority populationsPrEP provisionCare linkageHIV testingPrevention fundingSurvivors of sex traffickingPregnant peopleTransgender womenLife yearsCondom useHIV prevention fundsUS Centers for Disease Control and PreventionDisease Control and PreventionBaseline condom useControl and PreventionReduced condom useHuman immunodeficiency virus transmissionHeterosexual Black womenPreexposure prophylaxisHIV transmissionBlack women
2023
965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. 965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee. Open Forum Infectious Diseases 2023, 10: ofad500.2460. PMCID: PMC10678140, DOI: 10.1093/ofid/ofad500.2460.Peer-Reviewed Original ResearchHIV testingHIV prevention fundingHIV transmissionDeath avertedTransgender womenPregnant peopleHIV careRisk groupsCondom usePrevention fundingHIV testing ratesPre-exposure prophylaxisHIV testing frequencyPriority risk groupBlack womenHeterosexual Black womenNumber of peoplePrEP provisionVirologic suppressionIncident HIVUndiagnosed HIVHIV deathsPrEP usePotential ClinicalClinical impact
2019
The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India
Kazemian P, Costantini S, Kumarasamy N, Paltiel AD, Mayer KH, Chandhiok N, Walensky RP, Freedberg KA. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clinical Infectious Diseases 2019, 70: 633-642. PMID: 30921454, PMCID: PMC7319272, DOI: 10.1093/cid/ciz249.Peer-Reviewed Original ResearchConceptsHIV testing strategiesPreexposure prophylaxisHIV incidenceCost-effective HIV prevention strategyHuman immunodeficiency virus (HIV) preexposure prophylaxisHuman immunodeficiency virus (HIV) epidemicQuarterly HIV testingHigh HIV incidenceHigh-risk groupHIV prevention strategiesIndia-specific dataWorld Health OrganizationIndian MSMRoutine HIVHIV testHIV testingTesting strategiesPWIDPrevention strategiesHIVMean incidenceGross domestic productPrEPMSMHealth Organization
2017
An Adaptive Approach to Locating Mobile HIV Testing Services
Gonsalves GS, Crawford FW, Cleary PD, Kaplan EH, Paltiel AD. An Adaptive Approach to Locating Mobile HIV Testing Services. Medical Decision Making 2017, 38: 262-272. PMID: 28699382, PMCID: PMC5748375, DOI: 10.1177/0272989x17716431.Peer-Reviewed Original ResearchConceptsMobile HIV testingHIV testingMobile HIV testing servicesHIV testing resourcesUndetected HIV infectionHIV testing servicesCase detection ratePublic health agenciesUndiagnosed HIVHIV infectionHIV testHIV prevalenceUnknown prevalenceMore casesHealth agenciesDefinitions of hotspotsPrevalence informationTesting servicesPrevalenceSelection biasDetection rateSearch strategyHIV
2014
The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis
Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, Pei PP, Paltiel AD, Resch S, Freedberg KA, Peter T, Walensky RP. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLOS Medicine 2014, 11: e1001725. PMID: 25225800, PMCID: PMC4165752, DOI: 10.1371/journal.pmed.1001725.Peer-Reviewed Original ResearchConceptsCare CD4 testIncremental cost-effectiveness ratioCare CD4 testingPOC CD4CD4 testCD4 testingResource-limited settingsHIV diagnosisHIV testingClinical outcomesAntiretroviral therapy (ART) eligibilityPerson lifetime costsLife expectancyLifetime costsCost-effectiveness ratioResource limited settingsCost-effectiveness analysisSensitivity/specificityImmunological stagingLow sensitivity/specificityCost-effective thresholdLaboratory-based testsSurvivalEditors' SummaryOutcomesMobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness
Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, Paltiel AD, Wood R, Walensky RP, Losina E, Bekker LG, Freedberg KA. Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. PLOS ONE 2014, 9: e85197. PMID: 24465503, PMCID: PMC3898963, DOI: 10.1371/journal.pone.0085197.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioFacility-based testingHIV screeningHIV diagnosisFacility-based HIV testingFrequency of HIVUndiagnosed HIV prevalenceEarly HIV diagnosisLife expectancyMobile screening unitCost-effectiveness ratioResource-limited settingsCD4 countUndiagnosed HIVHIV testingHIV prevalenceCape TownClinical impactPopulation life expectancyMedical costsHIVScreening unitIntervention costsDiagnosisMedical facilities
2012
The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial
Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. Drug And Alcohol Dependence 2012, 128: 90-97. PMID: 22971593, PMCID: PMC3546145, DOI: 10.1016/j.drugalcdep.2012.08.009.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsSubstance abuse treatment programsNational HIV/AIDS StrategyCost-effectiveness ratioCommunity-based substance abuse treatment programsUndiagnosed HIV prevalenceRisk reduction counselingRapid HIV testingTreatment programHIV testingHIV prevalenceSite rapid testingSite rapid HIV testingHIV risk reduction counselingHIV/AIDS StrategyIncremental cost-effectiveness ratioHIV testing strategiesLife expectancyHIV testing offerPrior testing historyReceipt of resultsSubstance abuse treatmentRapid testingHIV screeningPatient demographics
2011
Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing
April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal Of General Internal Medicine 2011, 26: 661-667. PMID: 21286837, PMCID: PMC3101973, DOI: 10.1007/s11606-011-1637-5.Peer-Reviewed Original ResearchConceptsPotential survival gainsSurvival gainHIV testingDiagnosis rateAnnual HIV incidenceProportion of HIVUndiagnosed HIV prevalenceAnnual HIV diagnosis ratesHIV diagnosis ratesHIV incidenceHIV prevalenceEarly diagnosisHIVDisease controlLYGSurveillance dataAdult personsConsentConsent methodsPersonsPatientsConsent lawsBackgroundAlthoughDesignWeObjectiveTo
2010
Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impact
2009
HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies
April MD, Walensky RP, Chang Y, Pitt J, Freedberg KA, Losina E, Paltiel AD, Wood R. HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 310-316. PMID: 19582895, PMCID: PMC3209660, DOI: 10.1097/qai.0b013e3181a248e6.Peer-Reviewed Original ResearchConceptsART initiation ratesHIV testing ratesAntiretroviral treatmentTesting ratesHIV testingWorld Health Organization stageProvider-initiated testingFirst-time testersWorld Health Organization recommendationsMonths of eligibilityHigh-prevalence populationsHealth care facilitiesProportion of clientsMedian CD4Testing registersAnnual incidenceHIV servicesLate diagnosisPrevalence populationsTreatment trendsCare facilitiesStage distributionScreening policiesPatient recordsPopulation testingPrice, Performance, and the FDA Approval Process: The Example of Home HIV Testing
Paltiel AD, Pollack HA. Price, Performance, and the FDA Approval Process: The Example of Home HIV Testing. Medical Decision Making 2009, 30: 217-223. PMID: 19429837, PMCID: PMC2897074, DOI: 10.1177/0272989x09334420.Peer-Reviewed Original Research
2007
Cost-Effectiveness of HIV Testing and Treatment in the United States
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-Effectiveness of HIV Testing and Treatment in the United States. Clinical Infectious Diseases 2007, 45: s248-s254. PMID: 18190295, PMCID: PMC2365915, DOI: 10.1086/522546.Peer-Reviewed Original ResearchConceptsHIV testingVoluntary human immunodeficiency virus (HIV) testingHuman immunodeficiency virus (HIV) testingRoutine HIV testingVoluntary HIV testingLower cost-effectiveness ratioCost-effectiveness ratioCost-effectiveness studiesHealth care settingsPublic health importanceHealth care interventionsCost-effectiveness analysisImmunodeficiency syndromeRisk factorsCare interventionsUS CentersCare settingsVirus testingHealth effectivenessHealth importanceDisease controlRecent evidenceHIVNew guidelinesUnited States
2006
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals Of Internal Medicine 2006, 145: 797-806. PMID: 17146064, DOI: 10.7326/0003-4819-145-11-200612050-00004.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioDollars/QALYHIV prevalenceAnnual incidenceHIV infectionRoutine HIVAntiretroviral therapyIncremental cost-effectiveness ratioModerate HIV prevalenceUndetected HIV infectionVoluntary HIV screeningUndiagnosed HIV infectionRapid HIV testingHIV patient careHIV transmission riskOne-time screeningQuality-adjusted survivalLifetime medical costsServices Utilization SurveySecondary transmissionBase-case analysisCost-effectiveness analysisHIV screeningObservational cohortHIV testingRapid HIV testing at home: does it solve a problem or create one?
Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Annals Of Internal Medicine 2006, 145: 459-62. PMID: 16983134, DOI: 10.7326/0003-4819-145-6-200609190-00010.Peer-Reviewed Original ResearchConceptsRapid HIV testsHome HIV testHIV testHIV testingRapid home HIV testUnidentified HIV infectionRapid HIV testingHIV testing kitsHome HIV testingUndetectable diseaseFalse-negative resultsPublic health crisisHIV infectionHIV riskHIV detectionDrug AdministrationU.S. FoodHome testHIVHealth crisisHome useTesting kitsCareCautious perspectiveGreat need
2005
Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral. Medical Decision Making 2005, 25: 321-329. PMID: 15951459, DOI: 10.1177/0272989x05276955.Peer-Reviewed Original ResearchMeSH KeywordsAIDS SerodiagnosisComputer SimulationContinuity of Patient CareCost-Benefit AnalysisCounselingDecision Support TechniquesHIV InfectionsHumansInvestmentsMass ScreeningModels, StatisticalPatient Acceptance of Health CarePrevalenceProbabilityQuality-Adjusted Life YearsReferral and ConsultationResource AllocationSensitivity and SpecificityUnited StatesConceptsCost-effectiveness ratioScreening programUndiagnosed HIV prevalenceHealth screening programHIV testing servicesHIV testingHIV counselingHIV prevalenceLimited screening resourcesClinical impactAppropriate careQALYTesting pathwayTesting servicesScreening resourcesPathway outcomesOptimal targetingCarePathwayEarly stagesHIVReferralAdditional peopleFollowLater stages
1997
The Cost-Effectiveness of HIV Testing
Paltiel AD, Kaplan EH. The Cost-Effectiveness of HIV Testing. Medical Decision Making 1997, 17: 490-495. PMID: 9343808, DOI: 10.1177/0272989x9701700415.Peer-Reviewed Original ResearchConceptsNational surveillance surveyCost-effectiveness estimatesVoluntary HIVHIV testingSeroprevalence studySurveillance SurveyUninfected peopleTesting ratesUninfected individualsHIVInfectionDifferential participationPrevalenceLittle riskParticipation ratesMagnitude of resultsSeronegativesCost drivers
1996
Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy
Villari P, Fattore G, Siegel J, Paltiel A, Weinstein M. Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy. International Journal Of Technology Assessment In Health Care 1996, 12: 336-357. PMID: 8707505, DOI: 10.1017/s0266462300009673.Peer-Reviewed Original ResearchConceptsIntravenous drug usersEarly treatmentDrug usersHIV testing programsLife expectancyEffective early treatmentLow prevalence scenariosHealth care interventionsYears of lifeCost-effectiveness analysisHIV testingAsymptomatic subjectsCare interventionsPrevalence areasHigh prevalenceEconomic evaluationCost-effective procedureHIVPrevalenceTreatmentMore evidenceBehavior changeExpectancyCost savingsCohort